Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment

Clinical Microbiology Reviews

Volumn 12, Issue 2, 1999, Pages 298-309

  Domachowske, Joseph B ^a,c   Rosenberg, Helene F ^b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SUNY Health Science at Syracuse   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HISTAMINE; IMMUNOGLOBULIN E; NEUTRALIZING ANTIBODY;

ANIMAL MODEL; BRONCHIOLITIS; CELLULAR IMMUNITY; CHILD; EOSINOPHIL; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INFANT; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RODENT; T LYMPHOCYTE;

EID: 0032890867     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.12.2.298     Document Type: Review

References (194)

1. Ahern, W., T. Bird, and S. D. M. Court. 1970. Pathologic changes in virus infections of the lower respiratory tract in children. J. Clin. Pathol. 23:7-18.
2. Ahmad, A., J. Davies, S. Randall, and G. R. Skinner. 1996. Antiviral properties of extract of Opuntia streptacantha. Antiviral Res. 30:75-85.
3. + T cells. Clin. Exp. Immunol. 88:527-536.
4. American Academy of Pediatrics, Committee on Infectious Diseases, Committee on Fetus and Newborn. 1997. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 99:645-650.
5. Anderson, J. J., J. Norden, D. Saunders, G. L. Toms, and R. Scott. 1990. Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection. J. Gen. Virol. 71:1561-1570.
6. Anderson, L. J., C. Tsou, and C. Potter. 1994. Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells. J. Infect. Dis. 174:1201-1208.
7. Bangham, C. R. M., and B. A. Askonas. 1986. Murine cytotoxic T cells specific to respiratory syncytial virus recognize different antigenic subtypes of the virus. J. Gen. Virol. 67:623-629.
8. Bangham, C. R. M., M. J. Cannon, D. T. Karzon, and B. A. Askonas. 1985. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56:55-59.
9. Bangham, C. R. M., P. J. M. Openshaw, L. A. Ball, A. M. Q. King, G. W. Wertz, and B. A. Askonas. 1986. Human and murine cytotoxic T-cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137:3973-3977.
10. Barnard, D. L., C. L. Hill, T. Gage, J. E. Matheson, J. H. Huffman, S. W. Sidwell, M. I. Otto, and R. F. Schinazi. 1997. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res. 34:27-37.
11. Barry, W., F. Cockburn, R. Cornall, J. F. Price, G. Sutherland, and A. Vardag. 1985. Ribavirin aerosol for acute bronchiolitis. Arch. Dis. Child. 61:593-597.
12. Beem, M., R. Egerer, and J. Anderson. 1964. Respiratory syncytial virus neutralizing antibodies in persons residing in Chicago, Illinois. Pediatrics 34:761-770.
13. Brandt, C. D., H. W. Kim, and J. O. Arrobio. 1973. Epidemiology of respiratory syncytial virus infection in Washington, D.C. III. Composite analysis of eleven consecutive yearly epidemics. Am. J. Epidemiol. 98:355-364.
14. Bui, R. H., G. A. Molinar, J. D. Kettering, D. C. Heiner, D. T. Imagawa, and J. M. St. Geme, Jr. 1987. Virus-specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus. J. Pediatr. 110:87-90.
15. Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982.
16. Cannon, M. J., and C. R. M. Bangham. 1989. Recognition of respiratory syncytial virus fusion protein by mouse cytotoxic T-cell clones and a human cytotoxic T cell line. J. Gen. Virol. 70:79-87.
17. Cannon, M. J., E. J. Scott, G. Taylor, and B. A. Askonas. 1987. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T-cells. Immunology 62:133-138.
18. Cannon, M. J., P. J. M. Openshaw, and B. A. Askonas. 1988 Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168:1163-1168.
19. Chadwani, S., W. Borkowsky, K. Krasinski, R. Lawrence, and R. Welliver. 1990. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J. Pediatr. 117:251-254.
20. Chanock, R. M., A. Z. Kapikian, and R. H. Parrot. 1968. Possible role of immunologic factors in pathogenesis of RS virus lower respiratory tract disease. Perspect. Virol. 6:125-139.
21. Chanock, R. M., A. Z. Kapikian, J. Mills, H. W. Kim, and R. H. Parrot. 1970. Influence of immunologic factors in respiratory syncytial virus disease. Arch. Environ. Health 21:347-356.
22. Chanock, R. M., and R. H. Parrott. 1965. Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics 36:21-39.
23. Chanock, R. M., H. W. Kim, and A. J. Vargosko. 1961. Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 176:647-653.
24. Cherrie, A. H., K. Anderson, and G. W. Wetrz. 1992. Human cytotoxic T-cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J. Virol. 66:2102-2110.
25. Chiba, T., S. Shigeta, and Y. Numazaki. 1995. Inhibitory effect of pyridobenzazoles on virus replication in vitro. Biol. Pharm. Bull. 18:1081-1083.
26. Chiba, Y., Y. Higashidato, and K. Suga. 1989. Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection. J. Med. Virol. 28:133-139.
27. Chin, J., R. L. Maggoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
28. Cirino, N. M., G. Li, W. Xiao, P. F. Torrence, and R. H. Silverman. 1997. Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. USA 94:1937-1942.
29. Collins, P. L., and G. Mottet. 1992. Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J. Gen. Virol. 73:849-863.
30. Collins, P. L., and G. W. Wertz. 1986. Human respiratory syncytial virus genome and gene products, p. 40-46. In A. L. Notkins and M. B. A. Oldstone (ed.), Concepts in viral pathogenesis, vol. 2. Springer-Verlag, New York, N.Y.
31. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1351. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, vol. 2, 2nd ed. Lippencott-Raven Publishers, Philadelphia, Pa.
32. Collins, P. L., L. E. Dickens, A. Buckler-White, R. A. Olmsted, M. K. Spriggs, E. Camargo, and K. V. W. Coelingh. 1986. Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc. Natl. Acad. Sci. USA 83:4594-4598.
33. Collins, P. L., M. G. Hill, and P. R. Johnson. 1990. The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparisons of antigenic subgroups A and B and expression in vitro. J. Gen. Virol. 71:3015-3020.
34. Collins, P. L., M. G. Hill, J. Cristina, and H. Grosfeld. 1996. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc. Natl. Acad. Sci. USA 93:81-85.
35. Colocho Zelaya, E. A., C. Orvell, and O. Strannegard. 1994. Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus. Pediatr. Allergy Immunol. 5:100-106.
36. Committee on Infectious Disease, American Academy of Pediatrics. 1996. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97:137-140.
37. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66:1277-1281.
38. Connors, M., P. L. Collins, and C. Y. Firestone. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634-1637.
39. Cranage, M. P., and P. S. Gardner. 1980. Systemic cell mediated and antibody responses in infants with respiratory syncytial virus infections. J. Med. Virol. 5:161-170.
40. Crowe, J. E., B. R. Murphy, and R. M. Chanock. 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA 91:1386-1390.
41. Dickens, L. E., P. L. Collins, and G. W. Wertz. 1984. Transcriptional mapping of human respiratory syncytial virus. J. Virol. 52:364-369.
42. Domachowske, J. B., and H. F. Rosenberg. 1997. Eosinophils inhibit retroviral transduction of human target cells by a ribonuclease-dependent mechanism. J. Leukoc. Biol. 62:363-368.
43. Domachowske, J. B., K. D. Dyer, A. G. Adams, T. L. Leto, and H. F. Rosenberg. 1998. Eosinophil cationic protein/RNase 3 is another Rnase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res. 26: 3358-3363.
44. Domachowske, J. B., K. D. Dyer, C. A. Bonville, and H. F. Rosenberg. 1998. Recombinant human eosinophil-derived neurotoxin/Rnase 2 functions as an effective antiviral agent against respiratory syncytial virus. J. Infect. Dis. 177:1458-1464.
45. Domachowske, J. B., K. D. Dyer, and H. F. Rosenberg. 1997. Multiple signaling pathways are involved in respiratory syncytial virus induced chemokine expression. Clin. Infect. Dis. 25:390.
46. Domurat, F., N. J. Roberts, Jr., E. E. Walsh, and R. Dagan. 1985. Respiratory syncytial virus infection of human mononuclear leukocytes in vitro and in vivo. J. Infect. Dis. 152:895-902.
47. Falsey, A. R., and E. E. Walsh. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14:1214-1218.
48. Falsey, A. R., and E. E. Walsh. 1997. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15:1130-1132.
49. Fearns, R., M. E. Peebles, and P. L. Collins. 1997. Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology 236:188-201.
50. Feldslein, T., J. Swegarden, and G. Arwood. 1995. Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy. Pediatrics 96:14-17.
51. Fishaut, M., D. Tubergen, and K. McIntosh. 1980. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J. Pediatr. 96:179-186.
52. Foy, H. M., M. K. Cooney, and A. J. Maletzky. 1973. Incidence and etiology of pneumonia, croup, and bronchiolitis in preschool children belonging to a prepaid medical care group over a four-year period. Am. J. Epidemiol. 97:80-92.
53. Fulginetti, V. A., J. J. Eller, O. F. Seiber, J. W. Joyner, M. Minamitani, and G. Meiklejohn. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435-448.
54. Garcia, J., B. Garcia-Barreno, A. Vivo, and J. A. Melero. 1993. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein. Virology 195:243-247.
55. Gardner, P. S. 1977. How etiologic, pathologic, and clinical diagnoses can be made in a correlated fashion. Pediatr. Res. 11:254-261.
56. Gardner, P. S., J. McQuillin, and S. D. M. Court. 1970. Speculation on pathogenesis in death from respiratory syncytial virus infection. Br. Med. J. 1:327-330.
57. Garofalo, R., R. C. Welliver, and P. Ogra. 1989. Modulation of leukotriene (LT) release with ribavirin during infection with respiratory syncytial virus. Pediatr. Res. 25:163a. (Abstract.)
58. Garofalo, R., J. L. L. Kimpen, R. C. Welliver, and P. L. Ogra. 1992. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J. Pediatr. 120:28-32.
59. Glezen, W. P. 1977. Pathogenesis of bronchiolitis: epidemiologic considerations. Pediatr. Res. 11:239-243.
60. Glezen, W. P. 1987. Incidence of respiratory syncytial and parainfluenza type 3 viruses in an urban setting. Pediatr. Virol. 2:1-4.
61. Glezen, W. P., A. Paredes, and J. E. Allison. 1981. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J. Pediatr. 98:708-715.
62. Glezen, W. P., and F. W. Denny. 1973. Epidemiology of acute lower respiratory disease in children. N. Engl. J. Med. 288:498-505.
63. Golankiewicz, B., P. Januszczyk, S. Ikeda, J. Balzarini, and E. DeClercq. 1995. Synthesis and antiviral activity of benzyl-substituted imidazo[1,5-a]-1,3,5-triazine(5,8-diaza-7,9-dideazapurine) derivatives. J. Med. Chem. 38: 3558-3565.
64. Graham, B. S., T. Davis, Y. Tang, and W. Gruber. 1993. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr. Res. 34:167-172.
65. Graham, B. S., G. S. Henderson, Y. W. Tang, X. Lu, K. M. Neuzil, and D. J. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
66. Graham, B. S., L. A. Bunton, and J. Rowland. 1991. Respiratory syncytial virus infection in anti-μ treated mice. J. Virol. 65:4936-4942.
67. Graham, B. S., L. A. Bunton, and P. F. Wright. 1991. Reinfection of mice with respiratory syncytial virus. J. Med. Virol. 34:7-13.
68. Graham, B. S., L. A. Bunton, P. F. Wright, and D. T. Karzon. 1991. Role of T-lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88:1026-1033.
69. Groothius, J. R., E. A. F. Simoes, and M. J. Levin. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
70. Groothius, J. R., K. A. Woodin, and K. Katz. 1990. Early ribavirin treatment of respiratory syncytial virus infection in high-risk children. J. Pediatr. 117:792-798.
71. Groothius, J. R., S. J. King, D. A. Hogerman, P. R. Paradiso, and E. A. Simoes. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177:467-469.
72. Grosfeld, H., M. G. Hill, and P. L. Collins. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins: transcription also occurs under these conditions but requires RSV super-infection for efficient synthesis of full-length mRNA. J. Virol. 69:5677-5686.
73. Gruber, W. C., S. Z. Wilson, B. J. Throop, and P. R. Wyde. 1987. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection in the cotton rat. Pediatr. Res. 21:270-274.
74. Hall, C. B., E. E. Walsh, and K. C. Schnabel. 1990. The occurrence of groups A and B of respiratory syncytial virus over 15 years. The associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 162:1283-1290.
75. Hall, C. B., J. T. McBride, and E. E. Walsh. 1983. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection. N. Engl. J. Med. 308:1443-1447.
76. Hall, C. B., J. T. McBride, C. L. Gala, S. W. Hildreth, and K. C. Schnabel. 1985. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 254:3047-3051.
77. Hall, C. B., K. R. Powell, and N. E. MacDonald. 1986. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 315:77-81.
78. Hall, C. B., R. G. Douglas, and J. M. Geiman. 1975. Quantitative shedding patterns of respiratory syncytial virus in infants. J. Infect. Dis. 132:151-156.
79. Hall, C. B., R. G. Douglas, and J. M. Geiman. 1976. Respiratory syncytial virus infection in infants: quantitation and duration of shedding. J. Pediatr. 89:1-15.
80. Hall, C. B., R. G. Douglas, and J. M. Geiman. 1978. Interferon production in children with respiratory syncytial virus, influenza, and parainfluenza infections. J. Pediatr. 93:28-32.
81. Hardy, R. W., and G. W. Wertz. 1938. The production of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J. Virol. 72:520-526.
82. Harrison, A. M., C. A. Bonville, H. E. Rosenberg, and J. B. Domachowske. RSV-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am. J Resp. Crit. Care Med., in press.
83. Hasui, M., M. Matsuda, K. Okutani, and S. Shigeta. 1995. In vitro activities of sulfated polysaccharides from a marine microalga (Cochlodinium polykrikoides) against human immunodeficiency virus and other enveloped viruses. Int. J. Biol. Macromol. 17:293-297.
84. Heminway, B. R., Y. Yu, Y. Tanaka, K. G. Perrine, E. Gustafson, J. M. Bernstein, and M. S. Galinski. 1994. Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology 200:801-805.
85. Hemming, V. G., G. A. Prince, and R. L. Horswood. 1985. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J. Infect. Dis. 152:1083-1087.
86. Hemming, V. G., G. A. Prince, J. R. Groothius, and G. R. Siber. 1995. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:22-33.
87. Hildreth, S. W., and P. Paradiso. 1993. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:191-195.
88. Holberg, C. J., A. L. Wright, F. D. Martinez, C. G. Ray, L. M. Taussig, and M. D. Leibowitz. 1991. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am. J. Epidemiol. 133: 1135-1151.
89. Ikeda, S., J. Neyts, S. Verma, A. Wickramasinghe, P. Mohan, and E. DeClercq. 1994. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob. Agents Chemother. 38:256-259.
90. Isaacs, D. 1991. Viral subunit vaccines. Lancet 337:1223-1224.
91. Isaacs, D., C. R. M. Bangham, and A. J. McMichael. 1987. Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis. Lancet 2:769-771.
92. Jairath, S., P. B. Vargas, H. A. Hamlin, A. K. Field, and R. E. Kilkuskie. 1997. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. 33:201-213.
93. Johnson, P. R., M. K. Spriggs, R. A. Olmsted, and P. L. Collins. 1987. The G glycoprotein of human respiratory syncytial virus of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84:5625-5629.
94. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
95. Kapikian, A. Z., R. J. A. Bell, F. M. Mastrota, K. M. Johnson, R. J. Huebner, and R. M. Chanock. 1961. An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection. Am. J. Hyg. 74:234-248.
96. Karron, R. A., D. A. Buonagurio, A. F. Georgiu, S. S. Whitehead, J. E. Adamus, M. L. Clements-Mann, D. O. Harris, V. B. Randolph, S. A. Udem, B. R. Murphy, and M. S. Sidhu. 1997. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA 94:13961-13966.
97. Karron, R. A., P. F. Wright, J. E. Crowe, Jr., M. L. Clements-Mann, J. Thompson, M. Makhene, R. Casey, and B. R. Murphy. 1997. Evaluation of two live, cold passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, and in human adults, infants and children. J. Infect. Dis. 176:1428-1436.
98. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
99. Kim, H. W., J. O. Arrobio, and C. D. Brandt. 1973. Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory disease syndromes and temporal distribution of infection. Am. J. Epidemiol. 98:216-225.
100. Kim, H. W., S. L. Leikin, J. O. Arrobio, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr. Res. 10:75-78.
101. Kimpen, J. L. L., R. Garofalo, R. C. Welliver, and P. L. Ogra. 1992. Activation of human eosinophils in vitro by respiratory syncytial virus. Pediatr. Res. 32:160-164.
102. Kimpen, J. L. L., R. Garofalo, R. C. Welliver, K. Fujihara, and P. L. Ogra. 1996. An ultrastructural study of the interaction of human eosinophils with respiratory syncytial virus. Pediatr. Allergy Immunol. 7:48-53.
103. Klebanoff, S. J., and R. W. Coombs. 1996. Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 12:25-29.
104. Krilov, L. R., F. S. Mandel, and S. R. Barone. 1997. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. Pediatr. Infect. Dis. J. 16:273-276.
105. Krilov, L. R., R. M. Hendry, E. Godfrey, and K. McIntosh. 1987. Respiratory virus infection of peripheral blood monocytes: correlation with aging of cells and interferon production in vitro. J. Gen. Virol. 68:1749-1753.
106. Lambert, D. M., S. Barney, A. L. Lambert, K. Guthrie, R. Medinas, T. Bucy, J. Erickson, G. Merutka, and S. R. Petteway, Jr. 1996. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. USA 93:2186-2191.
107. Law, B., E. E. L. Wang, and N. MacDonald, 3 March 1997, posting date. Does ribavirin impact on the hospital course of children with respiratory syncytial virus infection? An analysis using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV database. Pediatrics 99. [Online.] http://www.pediatrics.org/cgi/content/full/99/3/e7. [26 February 1999, last date accessed.]
108. Levine, S., R. Klaiber-Franco, and P. R. Paradiso. 1987. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J. Gen. Virol. 68:2521-2524.
109. Lewinsohn, D. M., R. A. Bowden, D. Mattson, and S. W. Crawford. 1996. Phase 1 study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob. Agents Chemother. 40:2555-2557.
110. Long, C. E., K. Z. Voter, W. Barker, and C. Hall. 1997. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr. Infect. Dis. J. 16:1023-1028.
111. Macasaet, F. F., P. A. Kidd, and C. R. Balano. 1968. The etiology of acute respiratory infections. III. The role of viruses and bacteria. J. Pediatr. 72:829-839.
112. McConnochie, K. M., C. B. Hall, and E. E. Walsh. 1990. Variation in severity of respiratory syncytial virus infection with subtype. J. Pediatr. 117:52-62.
113. McConnochie, K. M., J. D. Mark, J. T. McBride, W. J. Hall, and J. G. Brooks. 1985. Normal pulmonary function measurements and airway reactivity in childhood after mild bronchiolitis. Pediatrics 107:54-58.
114. McIntosh, K. 1978. Interferon from nasal secretions from infants with viral respiratory tract infections. J. Pediatr. 93:33-36.
115. McIntosh, K., and J. M. Fishaut. 1980. Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. Prog. Med. Virol. 26:94-118.
116. McIntosh, K., H. B. Masters, I. Orr, R. K. Chao, and R. M. Barkin. 1978. The immunologic response to infection with respiratory syncytial virus in infants. J. Infect. Dis. 138:24-32.
117. McIntosh, K., J. McQuillin, and P. S. Gardner. 1979. Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection. Infect. Immun. 23:276-281.
118. Meert, K. L., A. P. Sarnaik, M. J. Gelmini, and M. W. Lieh-Lai. 1994. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double blind, randomized trial. Crit. Care Med. 22:566-572.
119. Meissner, H. C., D. R. Fulton, and J. R. Groothius. 1993. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob. Agents Chemother. 37:1655-1658.
120. Midulla, F., Y. T. Huang, I. A. Gilbert, N. M. Cirino, E. R. McFadden, Jr., and J. R. Panuska. 1989. Respiratory syncytial virus infection of human cord and adult blood monocytes and alveolar macrophages. Am. Rev. Respir. Dis. 140:771-777.
121. Milner, M. E., S. M. de la Monte, and G. M. Hutchins. 1985. Fatal respiratory syncytial virus infection in severe combined immunodeficiency. Am. J. Dis. Child. 135:1111-1114.
122. Moler, F. W., C. M. Steinhart, S. E. Ohmit, G. L. Stidham, and the Pediatric Critical Care Study Group. 1996. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J. Pediatr. 128:422-428.
123. Mufson, M. A., H. D. Levine, and R. E. Wasil. 1973. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am. J. Epidemiol. 98:88-95.
124. Muñoz, J. L., C. A. McCarthy, and M. E. Clark. 1991. Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cell. J. Virol. 65:4494-4497.
125. Murphy, B. R., A. Sotnikov, L. Lawrence, S. Banks, D. Alling, and G. Prince. 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8:497-502.
126. Murphy, B. R., D. W. Alling, and M. Snyder. 1986. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24:894-898.
127. Murphy, B. R., G. A. Prince, and E. E. Walsh. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:197-202.
128. Murphy, B. R., R. A. Olmsted, P. L. Collins, R. M. Chanock, and G. A. Prince. 1988. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J. Virol. 62:3907-3910.
129. Murphy, B. R., S. L. Hall, A. B. Kulkarni, J. E. Crowe, P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on the approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36.
130. Neyts, J., D. Reymen, D. Letourneur, J. Jozefonvicz, D. Scols, J. Este, G. Adrei, P. McKenna, M. Witvrouw, and S. Ikeda. 1995. Differential antiviral activity of derivatized dextrans. Biochem. Pharmacol. 50:743-751.
131. Nicholas, J. A., K. L. Rubino, and M. E. Levely. 1990. Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J. Virol. 64:4232-4241.
132. Nicholas, J. A., K. L. Rubino, M. E. Levely, A. L. Meyer, and P. L. Collins. 1991. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication. Virology 182:664-672.
133. Olmsted, R. A., and P. L. Collins. 1989. The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species. J. Virol. 63:2019-2029.
134. Opavsky, M. A., D. Stevens, and E. E. Wang. 1995. Testing models predicting severity of respiratory syncytial virus infection on the PICNIC RSV database. Arch. Pediatr. Adolesc. Med. 149:1217-1220.
135. Openshaw, P. J. 1995. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. J. Respir. Crit. Care Med. 152:59-62.
136. Openshaw, P. J. M., K. Anderson, and G. W. Wertz. 1990. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J. Virol. 64:1683-1689.
137. Padman, R., M. R. Bye, D. V. Schidlow, and N. Zaeri. 1985. Severe RSV bronchiolitis in an immunocompromised child. Clin. Pediatr. 24:719-721.
138. Panuska, J. R., M. I. Hertz, H. Taraf, A. Villani, and N. M. Cirino. 1992. Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients. Am. Rev. Respir. Dis. 145:934-939.
139. Paradiso, P. R., S. W. Hildreth, D. A. Hogerman, D. J. Speelman, J. Oren, and D. H. Smith. 1994. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24-48 months old. Pediatr. Infect. Dis. J. 13:792-798.
140. Parrot, R. H., H. W. Kim, and J. O. Arrobio. 1973. Epidemiology of respiratory syncytial virus infection in Washington. D.C. II. Infection and disease with respect to age, immunologic status, race and age. Am. J. Epidemiol. 98:289-300.
141. Pemberton, R. M., M. J. Cannon, and P. J. Openshaw. 1987. Cytotoxic T cell specificity for respiratory syncytial virus proteins: Fusion protein is an important target antigen. J. Gen. Virol. 68:2177-2182.
142. Piedra, P. A., S. Grace, A. Jewell, S. Spinelli, D. Bunting, D. A. Hogerman, F. Malinoski, and P. W. Hiatt. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15:23-31.
143. PREVENT Study Group. 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infant with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99.
144. Prince, G. A., B. A. Jensen, and V. G. Hemming. 1986 Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:721-728.
145. Prince, G. A., V. G. Hemming, R. L. Horswood, and R. M. Chanock. 1985. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 3:193-206.
146. Prober, C. G., and E. E. L. Wang. 1997. Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer. Pediatrics 99:472-475.
147. Randolph, A. G., and E. E. L. Wang. 1996. Ribavirin for respiratory syncytial virus lower respiratory tract infection: a systematic overview. Arch. Pediatr. Adolesc. Med. 150:942-947.
148. Richardson, L. S., R. B. Belshe, and D. L. Sly. 1978. Experimental respiratory syncytial virus pneumonia in cebus monkeys. J. Med. Virol. 2:45-59.
149. Richardson, L. S., R. H. Yolken, and R. B. Belshe. 1978. Enzyme linked immunosorbant assay for measurement of serologic response to respiratory syncytial virus infection. Infect. Immun. 23:660-664.
150. Rimensberger, P. C., and U. B. Schaad. 1994. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr. Infect. Dis. J. 13:328-330.
151. Rimensberger, P. C., A. Burek-Kozlowska, and A. Morell. 1996. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr. Infect. Dis. J. 15:209-216.
152. Rodriguez, W. J., H. W. Kim, and C. D. Brandt. 1987. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr. Infect. Dis. J. 6:159-163.
153. Rodriguez, W. J., W. Gruber, R. C. Welliver, J. R. Groothius, E. A. F. Simoes, H. C. Meissner, V. G. Hemming, C. B. Hall, M. L. Lepow, A. J. Rosas, C. Robertsen, and A. A. Kramer for the Respiratory Syncytial Virus Immune Globulin Study Group. 1997. Respiratory syncytial virus (RSV) immunoglobulin therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics 99:454-461.
154. Rosner, I., R. C. Welliver, P. Edelson, K. Geraci-Ciardullo, and M. Sun. 1987. Effect of ribavirin therapy on RSV-specific IgE and IgA responses after infection. J. Infect. Dis. 155:1043-1047.
155. Saito, T., R. W. Deskin, A. Casola, H. Haeberle, B. Olszewska, P. B. Ernst, R. Alam, P. L. Ogra, and R. Garofalo. 1997. Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. 175:497-504.
156. Shigeta, H., Y. Hinuma, and T. Suto. 1968. The cell to cell infection of respiratory syncytial virus in HEp-2 monolayer cultures. J. Gen. Virol. 3:129-131.
157. Siber, G. R., R. D. Leombruno, and J. Leszczynski. 1994. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis. 169: 1368-1373.
158. Sigurs, N., R. Bjarnason, and F. Sigurbergsson. 1994. Eosinophil cationic protein in nasal secretion and in serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: relation to asthma and atopy. Acta Paediatr. 83:1151-1155.
159. Simoes, E. A. F., H. M. Sondheimer, and H. C. Meissner. 1996. Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease. Pediatr. Res. 662:113A. (Abstract.)
160. Smith, D. W., L. R. Frankel, L. H. Mathers, A. T. S. Tang, R. L. Ariaggno, and C. G. Prober. 1991. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N. Engl. J. Med. 325:24-29.
161. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:421-432.
162. Stark, J. M., V. Godding, J. B. Sedgewick, and W. W. Busse. 1996. Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. J. Immunol. 156:4774-4782.
163. Sterner, G., S. Wolontis, B. Bloth, and G. DeHevesy. 1966. Respiratory syncytial virus: an outbreak of acute respiratory illnesses in a home for infants. Acta Paedriatr. Scand. 55:273-279.
164. Suffin, S. C., G. A. Prince, K. B. Muck, and D. D. Porter. 1979. Immunoprophylaxis of respiratory syncytial virus in the infant ferret. J. Immunol. 123:10-14.
165. Taber, L. H., V. Knight, and B. E. Gilbert. 1983. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72:613-618.
166. Taylor, C. E., A. W. Craft, and J. Kernahan. 1990. Local antibody production and respiratory syncytial virus infection in children with leukemia. J. Med. Virol. 30:277-281.
167. Taylor, C. E., S. Morrow, and M. Scott. 1989. Comparative virulence of respiratory syncytial virus subgroups A and B. Lancet i:777-778.
168. Taylor, G., J. Furze, and P. R. Tempest. 1991. Humanized monoclonal antibody to respiratory syncytial virus. Lancet 337:1411-1422.
169. Taylor, G., E. J. Scott, and A. J. Hayle. 1985. Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus. J. Gen. Virol. 66: 2533-2588.
170. Torrence, P. F., W. Xiao, G. Li, H. Cramer, M. R. Player, and R. H. Silverman. 1997. Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev. 7:203-206.
171. Tristram, D. A., R. C. Welliver, W. L. Hicks, Jr., and R. Hard. 1997. Ciliated human respiratory epithelium: a new model for respiratory syncytial virus (RSV) infection. Pediatr. Res. 41:131A. (Abstract.)
172. Tristram, D. A., R. C. Welliver, D. A. Hogerman, S. W. Hildreth, and P. Paradiso. 1994. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 12:551-556.
173. Tristram, D. A., R. C. Welliver, K. Mohar, D. A. Hogerman, S. W. Hildreth, and P. Paradiso. 1993. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:191-195.
174. VanAerschot, A. A., P. Mamos, N. J. Weyns, S. Ikeda, E. DeClercq, and P. A. Herdewijn. 1993. Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkylating reagent. J. Med. Chem. 36:2938-2942.
175. Volovitz, B., H. Faden, and P. L. Ogra. 1988. Release of leukotriene C4 in respiratory tract during acute viral infection. J. Pediatr. 112:218-222.
176. Walsh, E. E., K. M. McConnochie, C. E. Long, and C. B. Hall. 1997. Severity of respiratory syncytial virus infection is related to virus strain. J. Infect. Dis. 175:814-820.
177. Walsh, E. E., and J. Hruska. 1983. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J. Virol. 47: 171-177.
178. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Purification and characterization of GP90, one of the enveloped glycoproteins of respiratory syncytial virus. J. Gen. Virol. 65:761-767.
179. Wang, E. E. L., B. J. Law, and F. D. Boucher. 1996. Pediatric investigators collaborative network in infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial lower respiratory tract infection. J. Pediatr. 129:390-395.
180. Wathen, M. W., P. A. Aeed, and A. P. Elhammer. 1991. Characterization of oligosaccharide structures on a chimeric respiratory syncytial virus protein expressed in insect cell line Sf9. Biochemistry 30:2863-2868.
181. Watt, P. J., M. Zardis, and P. R. Lambden. 1986. Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants. Clin. Exp. Immunol. 64:503-509.
182. Weiss, S. T., I. B. Tager, F. E. Speizer, and B. Rosner. 1980. Persistent wheeze: its relation to respiratory illness, cigarette smoking, and level of pulmonary function in a population sample of children. Am. Rev. Respir. Dis. 122:697-707.
183. Welliver, R. 1993. The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years. Pediatr. Pulmonol. 15:19-27.
184. Welliver, R. C., D. T. Wong, M. Sun, E. Middleton, R. S. Vaughn, and P. L. Ogra. 1981. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N. Engl. J. Med. 305:841-846.
185. Welliver, R. C., L. A. Kaul, and P. L. Ogra. 1979. Cell-mediated immune response to respiratory syncytial virus infection: relationship to the development of reactive airway disease. J. Pediatr. 94:370-375.
186. Welliver, R. C., T. N. Kaul, M. Sun, and P. L. Ogra. 1984. Defective regulation of immune responses in respiratory syncytial virus infection. J. Immunol. 133:1925-1930.
187. Welliver, R. C., T. N. Kaul, and P. L. Ogra. 1980. The appearance of cell bound IgE in respiratory tract epithelium after respiratory syncytial virus infection. N. Engl. J. Med. 303:1198-1202.
188. Whimbey, E., R. E. Champlin, J. A. Englund, N. Q. Mirza, P. A. Piedra, J. M. Goodrich, D. Przepiorka, M. A. Luna, R. C. Morice, and J. L. Neumann. 1995. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 16:393-399.
189. Wheeler, J. G., J. Wofford, and R. B. Turner. 1993. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 12:209-213.
190. Wyde, P. R., D. K. Moore, T. Hepburn, C. L. Silverman, T. G. Porter, M. Gross, G. Taylor, S. G. Demuth, and S. B. Dillon. 1995. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:543-550.
191. Wyde, P. R., D. K. Moore, D. M. Pimentel, and H. A. Blough. 1995. Evaluation of the antiviral activity of N-(phosphonoacetyl)-L-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Res. 27:59-69.
192. Wyde, P. R., D. K. Moore, D. M. Pimentel, B. E. Gilbert, R. Nimrod, and A. Panel. 1996. Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats. Antiviral Res. 31:173-184.
193. Wyde, P. R., M. W. Ambrose, L. R. Meyerson, and B. E. Gilbert. 1993. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats. Antiviral Res. 20:145-154.
194. Yu, Q., R. W. Hardy, and G. W. Wertz. 1995. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal transacting requirements for RNA replication. J. Virol. 69:2412-2419.